



Financial Tear Sheet

Corporate Profile

Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

Primary IR Contact

Kristin Hodous

Blueprint Medicines

Phone: 617-714-6674

E-mail:

khodous@blueprintmedicines.com

Stock Information

BPMC (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price **\$81.53**

Change (%) ▼ **0.63 (0.77%)**

Volume 3,455

52 Week Low \$25.34

Market Cap \$3,220,934,912

Rolling EPS -3.42

PE Ratio 0

Shares Outstanding 39,203,200

Data as of December 14, 2017 9:31 a.m. ET



Recent Press Releases & Upcoming Events

December 12, 2017

[Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock](#)

December 11, 2017

[Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock](#)

December 10, 2017

[Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib \(BLU-285\) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity](#)

There are currently no events scheduled.

SEC Filings

Filing Date

Form

December 13, 2017

424B5

December 11, 2017

424B5

December 11, 2017

8-K

November 24, 2017

4

Corporate Governance

[Jeffrey Albers](#)

Chief Executive Officer

[Marion. Dorsch, Ph.D](#)

Chief Scientific Officer

[Anthony Boral,](#)

Chief Medical

M.D-Ph.D.

Officer

Kate Haviland

Chief Business
Officer

Christoph Lengauer,
Ph.D.

Executive Vice
President

Data provided by Nasdaq. Minimum 15 minutes delayed.